MidesteineAlternative Names: MR 889
Latest Information Update: 25 Feb 2008
At a glance
- Originator Medea Research
- Developer Medea Research; Pulitzer
- Class Expectorants
- Mechanism of Action Chymotrypsin inhibitors; Leucocyte elastase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma; Bronchitis; Cystic fibrosis; Emphysema